High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

John P. Veluchamy1,2 · A. Marijne Heeren1,3 · Jan Spanholtz2 · Jaap D. H. van Eendenburg4 · Daniëlle A. M. Heideman5 · Gemma G. Kenter3 · Henk M. Verheul1 · Hans J. van der Vliet1 · Ekaterina S. Jordanova3 · Tanja D. de Gruijl1

Abstract Down-regulation of HLA in tumor cells, low numbers and dysfunctionality of NK cells are commonly observed in patients with end-stage cervical cancer. Adoptive transfer of high numbers of cytotoxic NK cells might be a promising treatment approach in this setting. Here, we explored the cytotoxic efficacy on ten cervical cancer cell lines of activated allogeneic NK cells from two sources, i.e., peripheral blood (PBNK) with and without cetuximab (CET), a tumor-specific monoclonal antibody directed against EGFR, or derived from umbilical cord blood (UCB-NK). Whereas CET monotherapy was ineffective against the panel of cervical cancer cell lines, irrespective of their EGFR expression levels and despite their RASwt status, it significantly enhanced the in vitro cytotoxic efficacy of activated PBNK ($P = 0.002$). Equally superior cytotoxicity over activated PBNK alone was achieved by UCB-NK ($P < 0.001$). Both PBNK- and UCB-NK-mediated cytotoxic activity was dependent on the NK-activating receptors natural killer group 2, member D receptor (NKG2D) and DNAX accessory molecule-1 (DNAM-1) ($P < 0.05$) and unrelated to expression levels of the inhibitory receptors HLA-E and/or HLA-G. Most strikingly, whereas the PBNK’s cytotoxic activity was inversely correlated with HLA-ABC levels ($P = 0.036$), PBNK + CET and UCB-NK cytotoxicity were entirely independent of HLA-ABC expression. In conclusion, this study provides a rationale to initiate a clinical trial for cervical cancer with adoptively transferred allogeneic NK cells, employing either UCB-NK or PBNK + CET for EGFR-expressing tumors. Adoptive transfer of UCB-NK might serve as a generally applicable treatment for cervical cancer, enabled by HLA-, histology- and HPV-independent killing mechanisms.

Keywords Cervical cancer · Peripheral blood NK cells · Umbilical cord blood stem cell-derived NK cells · CET · NK ligands and receptors · Adoptive NK immunotherapy

Abbreviations

7AAD 7-Aminoactinomycin D
ADCC Antibody-dependent cell-mediated cytotoxicity
CET Cetuximab
DNAM-1 DNAX accessory molecule-1
KIR2D Killer-cell immunoglobulin-like receptor 2D
MICA/B Major histocompatibility complex class I polypeptide-related sequence A/B
NKG2A/C/D Natural killer group 2, member A/C/D receptor


**Introduction**

Persistent infection of the cervical epithelium by high-risk HPV can lead to cervical intraepithelial neoplasia which may progress to invasive cervical cancer, such as squamous cell carcinoma, adenosquamous cell carcinoma or adenocarcinoma [1–3].

Treatment for cervical cancer includes conventional surgery, chemotherapy and/or radiation. In addition, in advanced (metastatic) disease, targeted therapies are widely explored. Unfortunately, targeted intervention strategies using small molecules, angiogenesis inhibitors and monoclonal antibodies directed against specific tumor antigens and proliferation pathways have had limited success in restricting cervical tumor growth so far [4, 5]. In cervical cancer, EGFR is variably expressed in 80 % of the tumor tissues [6]. Overexpression of EGFR has been associated with poor prognosis in cervical cancer, making EGFR an obvious candidate for therapeutic targeting [7, 8]. However, treatment with cetuximab (CET) (chimeric IgG1, anti-EGFR mAb) as monotherapy or CET in combination with chemotherapy was ineffective in patients with cervical cancer, in spite of the apparent absence of activating mutations in the EGFR pathway [9, 10].

Immunotherapy of cervical cancer has been clinically explored with limited success. Efforts so far have mostly focused on vaccination approaches against HPV-derived oncogenes (E6 and E7) to trigger an efficacious antitumor T cell response [11]. Failure to improve clinical outcome may at least in part be due to extensive HLA down-regulation commonly observed in cervical cancer [12, 13] (Heeren et al. 2015, submitted). In these cases, NK cell-based therapies may prove more effective than T cell-based approaches. Indeed, the role of the innate immune response in host defense and viral clearance during (early) infection is well recognized [14]. NK cells are potent in exerting rapid cytotoxicity by releasing cytotoxic granyme B and perforin in order to lyse virus-infected cells and tumor cell targets. Functional activity of NK cells is regulated by an equilibrium between inhibitory (e.g., CD94/NKG2A) and activating (e.g., CD16, DNAM-1, CD94/NKG2C, CD94/NKG2D) receptors [15, 16].

Infiltrating NK cells are observed in low-grade and high-grade cervical intraepithelial neoplasia lesions and to a lesser extent in cervical carcinoma [13, 17–20]. In vitro studies have shown that peripheral blood NK cells (PBNK) are able to kill HPV-infected cell lines [18, 20, 21]. However, NK cells are often dysfunctional and low in number in cervical cancer patients and thereby unable to mount efficient cytotoxicity against tumors [22, 23]. NK cytotoxic function is also counteracted by several cervical tumor escape mechanisms, including low expression of activating NK cell receptor ligands (e.g., MICA/B, ULBPs, Nectin, PVR) and aberrant expression of suppressive non-classical HLA molecules (e.g., HLA-E and -G) by tumor cells [18, 24–26] (Heeren et al. 2016, submitted). Ex vivo expanded autologous NK cells, adoptively transferred for the treatment of solid tumors, in most studies have yielded disappointing results, underscoring the dire need for the development of more powerful therapeutic approaches to overcome tumor-associated NK cell dysfunctionality and the inherent resistance to cytolysis of cancer cells. Clinical studies exploring the use of ex vivo expanded allogeneic PBNK from healthy donors also yielded low antitumor efficacy [27, 28], which may have been due to their limitations in terms of cell yield, purity, ability to expand in vivo and cytotoxic capacity [29].

An attractive alternative approach would be the use of umbilical cord blood CD34+ stem cell-derived NK cells (UCB-NK), which are feeder cell-free cultures that can be differentiated and efficiently expanded up to 10,000-fold, resulting in a highly pure product with a high cytolytic capacity [30]. Yet another alternative might be to enhance PBNK cell-mediated cytolysis of cervical tumor cells by the tumor-targeted IgG1 monoclonal antibody CET, to invoke antibody-dependent cell-mediated cytotoxicity (ADCC) [31].

In this comparative study, we explored the antitumor efficacy of two clinically applicable therapeutic strategies, i.e., UCB-NK versus allogeneic PBNK + CET, for cervical cancer. Of note, the combination with CET is not a viable option for UCB-NK as in vitro they do not express sufficient levels of the required Fc receptor CD16 to obtain functional benefit [32] (Veluchamy et al., manuscript in preparation). A series of in vitro NK cytotoxicity assays was conducted to compare antitumor potency of PBNK from healthy volunteers, with or without co-incubation with CET with that of umbilical cord blood-derived NK cell (UCB-NK) monotherapy against various cervical cancer cell lines. These cell lines (n = 10) were stratified based on infection with different HPV types, histological origins and differential expression levels of NK-activating and inhibitory ligands. The findings from this preclinical study strongly support the use of allogeneic UCB-NK derived from umbilical cord precursor cells and outline the advantages of their use as monotherapy in the treatment of cervical cancer.
Materials and methods

Cell lines

Cervical cancer cell lines CSCC7, CC8, CC10A, CC10B, CC11A and CC11B were generated in the Department of Pathology of Leiden University Medical Center (The Netherlands) from primary tumors as described previously [33]. These patient-derived cell lines as well as commercially obtained cervical cancer-derived cell lines, HeLa, SiHa, CaSki and C33A (American Type Culture Collection) were maintained in DMEM (Lonza) medium containing 4.5 g/L glucose, 10 % FCS (Hyclone), 10 µg/mL gentamicin and 0.25 µg/mL amphotericin B (Gibco), 100 units penicillin/100 units streptomycin/0.3 mg/mL glutamine (Thermo Fisher Scientific). Cell cultures were maintained at 37 °C in a humidified atmosphere containing 5 % CO2. See Table 1 for cell line characteristics.

Phenotyping of cervical cancer cell lines

To phenotype cervical cancer cell lines, cell suspensions in PBS supplemented with 0.1 % BSA and 0.02 % NaN3 (FACS buffer) were stained for 30 min at 4 °C using antibodies to HLA-ABC (clone w6/32, Immunotools) (labeled with FITC), HLA-E (clone 3D12HLA-E, eBioscience), HLA-G (clone 87G, Biolegend), EGFR (clone EGFR.1, BD Biosciences), PVR (clone SK11.4, Biolegend), MICA/B (clone 6D4, Biolegend), ULBP2/5/6 (clone #165903, R&D systems), ULBP1 (clone #170818, R&D systems) and ULBP3 (clone #166510, R&D systems) (all labeled with PE). IgG1, IgG2a and IgG2b isotype antibodies were used as negative controls. After incubation, the cells were washed with FACS buffer and analyzed using a flow cytometer LSR Fortessa (BD Biosciences). Phenotypic analyses were obtained from at least two independent experiments performed on each cell line. Data were analyzed using Kaluza software (Beckman coulter) and calculated as specific (geometric) mean fluorescence intensity (MFI) (MFI; geometric mean fluorescence of marker — geometric mean fluorescence of isotype).

RAS typing

RAS status was obtained from rational molecular assessments and innovative drugs selection (RAIDs) project data (http://www.raids-fp7.eu/project-overview.html) and www.lgcstandards-atcc.org for cell lines HeLa, SiHa, CaSki, C33A, CSCC7, CC10A and CC10B. In addition, full RAS typing (i.e., BRAF exon 15, KRAS exon 2–4 and NRAS exon 2–4) was performed for cell lines CC8, CC11A and CC11B at the molecular pathology lab of the Department of Pathology of the VU University Medical Center (Amsterdam, The Netherlands) using high-resolution melting assay followed by Sanger sequencing of using high-resolution melting PCR products with an aberrant melt curve, essentially as described previously [34, 35].

PBMC isolation and NK cell isolation

Whole blood samples from four healthy volunteers were collected. PBMC were isolated using Lymphoprep™ (STEMCELL Technologies, The Netherlands) density gradient centrifugation. CD56+ NK cells were isolated from PBMC using a MACS® Human NK cell isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. The cell number and purity of the isolated PBNK was analyzed by flow cytometry. Isolated NK cells were activated overnight with 1000 U/mL IL-2 (Proleukin®; Chiron, München, Germany) and 10 ng/mL IL-15 (CellGenix) before use in cytotoxicity assays. NK cell purity and viability were checked by flow cytometry using the following antibodies: 7-aminoactinomycin D (7AAD; Sigma-Aldrich), CD3 (labeled with VioBlue), CD56 (labeled with APC-Vio770) and CD16 (labeled with APC) (all from Miltenyi Biotech). Purity of NK cells obtained from NK donors was 87 ± 6 %. For cytotoxicity assays, only PBNK with CD16 expression rates exceeding 80 % were used.

UCB-NK isolation and cultures

Allogeneic NK cells were generated from cryopreserved umbilical cord blood hematopoietic stem cells as previously described [36]. CD34+ UCB cells (3 × 10⁶ mL) were plated into 12-well tissue culture plates (Corning...
In vitro NK cytotoxicity assays

Cervical cancer cell lines (target cells) were labeled with 5 µM pacific blue succinimidyl ester (PBSE; Molecular Probes Europe, Leiden, The Netherlands) in a concentration of 1 x 10^7 cells/mL for 15 min at 37 °C. After incubation, cells were washed and resuspended in DMEM culture medium to a final concentration of 1 x 10^6 mL. PBNK and UCB-NK were washed with PBS and also resuspended in GBGM medium to a final concentration of 1 x 10^6 mL. Target cells were co-cultured in triplicate with effector cells (PBNK or UCB-NK), with or without 5 µg/mL CET at an E:T ratio of 1:1 in a total volume of 100 µL in FACs tubes (5 x 10^4 targets in 50 µL of DMEM culture medium incubated with 5 x 10^5 effectors in 50 µL of GBGM medium). PBNK, UCB-NK and target cells alone were cultured in triplicate as controls. To measure degranulation by PBNK and UCB-NK, anti-CD107a PE (Miltenyi Biotech, Germany) was added at the beginning of the assay. After incubation for 4 h at 37 °C, cells were harvested and stained with 7AAD, CD56 (labeled with APC-Vio770) and CD16 (labeled with APC) (all from Miltenyi Biotech, Germany). For NK flow cytometry and blocking experiments, NKG2D FITC (clone ON72, Beckman Coulter) and DNAM-1 FITC (clone DX11, BD Pharmingen™) were used at 10 µg/mL. Further, killer-cell immunoglobulin-like receptor 2D (PanKIR2D), FITC (clone NKVFS1) and CD94/NKG2A PE-Vio770 (clone REA110) (both from Miltenyi Biotech) were used to screen inhibitory receptor expression on PBNK and UCB-NK. BD LSR Fortessa™ was used for readout of the cytotoxicity assays. Data were analyzed using Kaluza software (Beckman coulter). Percentages of specific NK degranulation were calculated as ∆CD107a + NK cells [i.e., (target cells + NK cells) – (NK cells only)] and percentages of cytotoxicity as ∆7AAD + target cells [i.e., (target cells + NK cells) – (target cells only)]. See Supplementary Figure 1 for a representative gating example.

Statistical analysis

Statistical significance of differences between conditions were determined using a parametric paired t test, unpaired t test or a one-way ANOVA with Bonferroni’s multiple comparison test and a two-way ANOVA with multiple comparisons between column means. Correlation analyses between percentages NK degranulation, cytotoxicity and MFI were performed using Pearson’s analysis. A P value of <0.05 was considered statistically significant.

Results

Comparative analysis of NK cell cytotoxic activity against cervical cancer cell lines

Initially, we compared the antitumor potency of healthy activated PBNK in the presence or absence of CET. Ten cervical cancer cell lines (EGFR-expressing except for C33A, and all RAS wt; Table 1) were subjected to PBNK only, CET only, or to a combination of PBNK with CET in order to examine ADCC effects. In line with previous studies, CET as monotherapy did not induce cell death in any of the cell lines tested (data not shown). However, cervical cancer cell lines were sensitive in varying degrees to PBNK-induced cell lysis (Fig. 1a), independent of their EGFR expression levels (Fig. 1b), with consistently and significantly higher cytotoxicity rates when coated with CET (P = 0.002) (Fig. 1c). C33A (EGFR-negative cell line) was the only cell line that did not display a higher cytotoxicity rate when PBNK were combined with CET (Fig. 1a–c).

Next, activated PBNK were compared with UCB-NK for their ability to induce target cell death. UCB-NK was significantly more cytotoxic than PBNK, consistently inducing higher rates of tumor cell death in all tested cell lines (P < 0.001) (Fig. 2a, b). Note that the PBNK cytotoxicity data presented in Fig. 2a are the same as those in Fig. 1a. The cytotoxicity levels were similar for UCB-NK and PBNK + CET (Figs. 1a, 2a). This was further borne out by observed degranulation levels of NK cells in response to exposure to the cervical cancer cell lines, as measured by...
CD107a surface expression. These were comparably and significantly elevated in the PBNK + CET and UCB-NK conditions over PBNK alone (Fig. 2c, Supplementary Figure 2). UCB-NK were not tested in combination with CET due to their low surface expression of CD16a, which is essential for ADCC in combination with therapeutic mAbs (data not shown). Interestingly, PBNK degranulation levels were low in combination with CET upon exposure to cervical cancer cell lines expressing low levels of EGFR (C33a, HeLa, SiHa, CC11B, CC11A, CC10B, CC10A, CaSki and two experiments with two different PBNK donors for CSCC7 and CC8). Bars represent mean ± SEM. c Significantly higher cytotoxicity levels (Δ7AAD) were observed in all cell lines after co-culture with PBNK + CET compared to PBNK, except for C33A (open circle). *P < 0.05 and **P < 0.01 calculated with paired t test per histological subtype and HPV type of cervical cancer cell lines are shown in Supplementary Figure 3. It shows that irrespective of HPV or histological tumor type, highest cytotoxicity was consistently achieved by UCB-NK.

**Expression of NK-activating receptors and their ligands and their contribution to mediating cytotoxicity**

To investigate the involvement of activating receptors in mediating the cytotoxic activity of PBNK and UCB-NK, the expression of the two major NK-activating receptors DNAM-1 and NKG2D on the NK cells described to be involved in the recognition of cervical cancer cells, and their respective ligands, i.e., PVR and MICA/B, ULBP,
### NK activating receptors

|              | DNAM-1 | NKG2D |
|--------------|--------|-------|
|              | MICA/B | ULBP1 | ULBP3 | ULBP2/5/6 |
| C33A         | 138.25 | 1.37  | 3.70  | 4.47      | 1.15   |
| HeLa         | 517.47 | 9.72  | 10.39 | 9.49      | 25.37  |
| SiHa         | 423.85 | 4.64  | 10.05 | 7.76      | 116.66 |
| CC11B        | 144.75 | 0.79  | 5.53  | 6.55      | 15.62  |
| CC11A        | 158.67 | 0.49  | 4.76  | 4.10      | 64.07  |
| CC10B        | 537.47 | 2.26  | 5.77  | 8.75      | 55.62  |
| C33c7        | 184.38 | 0.78  | 4.43  | 4.23      | 62.10  |
| CC10A        | 403.39 | 4.77  | 7.99  | 10.76     | 44.11  |
| CaSki        | 420.56 | 11.17 | 9.72  | 14.31     | 63.32  |
| CC8          | 252.31 | 1.78  | 10.85 | 17.48     | 47.01  |

#### Experimental setup
- **DNA-M1** and **NKG2D** expression levels in different cell lines.
- **Cytotoxicity assay** results showing percentage of cytotoxicity.
- **PBNK** and **UCB-NK** cells treated with IL-2 + IL-15.

#### Results
- **C33A** cells show high DNAM-1 expression compared to NKG2D.
- **HeLa** cells exhibit a notable expression of MICA/B and ULBP2/5/6.
- **SiHa** cells display moderate ULBP1 and ULBP3 expression.
- **CC11B** and **CC11A** cells show low ULBP1 and moderate ULBP3 expression.
- **CC10B** and **C33c7** cells demonstrate higher ULBP1 and moderate ULBP3 expression.
- **CC10A** and **CaSki** cells exhibit high ULBP1 and moderate ULBP3 expression.
- **CC8** cells show high ULBP1 and moderate ULBP3 expression.

#### Immunological Response
- **DNA-M1** and **NKG2D** blocking in NK control, DNAM blocking, NKG2D blocking, and NKG2D + DNAM blocking conditions.
on the tested cervical cancer cell lines, were assessed. Similarly, high levels of DNAM-1 and NKG2D were observed on both PBNK and UCB-NK (Fig. 3a). The cell lines showed differential expression of the NK-activating ligands, but all were positive for PVR, the DNAM-1 ligand, and at least one of the NKG2D ligands (Fig. 3b). From the panel of cell lines, SiHa (with highest expression levels of PVR and ULBP-2/5/6) and C33A (with lowest expression levels of PVR and ULBP-2/5/6) were selected as target cells in functional blocking studies. The relatively low ligand expression levels on C33A required combined blocking of DNAM-1 and NKG2D to achieve a significant reduction in either PBNK- or UCB-NK-mediated cytotoxicity (Fig. 3b). In contrast, blocking either DNAM-1 or NKG2D already led to significant reductions of cytotoxicity in SiHa cells (Fig. 3c). These data show dependence (at least in part) of both PBNK and UCB-NK on DNAM-1 and NKG2D for their cytotoxic potency.

**Discussion**

Cervical cancer is the fourth most common malignancy in women worldwide. Survival is severely reduced in case of lymph node metastasis, with no curative treatment options available. In cervical cancer, ACT involving T cell or NK cell-based therapies has not yet been widely explored, but they have been successfully applied in the treatment of various other cancer types [38–40]. In one clinical trial, adoptive transfer of tumor-infiltrating T cells in metastatic cervical cancer resulted in tumor responses in 3/9 patients with complete remission in 2/9 patients [41]. These findings suggest that ACT could be a viable treatment option for some patients with cervical cancer. However, most cervical tumors have HLA class I alterations and will therefore not respond completely to T cell-based therapies [13, 42] (Heeren et al., submitted). NK cell-based therapies present a viable alternative in that case, but in advanced cervical cancer, these effector cells are often impaired in their functionality [23, 24]. In this study, we therefore explored the possible therapeutic efficacy of allogeneic NK cells. Clinically applicable NK cells may be derived from two sources, i.e., NK cells derived from peripheral blood and NK cells cultured and expanded from umbilical cord blood stem cells. We tested their cytotoxic efficacy (with and without CET for PBNK) on ten cervical cancer cell lines representing different histological subtypes, HPV types and expressing differential levels of NK-activating and inhibitory ligands.

Initially, we investigated the effect of PBNK alone and a combination of PBNK with CET on the cervical cancer cell lines. From the literature, it is known that cervical tumors often present with variable levels of EGFR [6, 8]. In colorectal cancers, mutant KRAS is associated with resistance to CET [43]. Although most of the cervical cancer cell lines were EGFR positive and all were $R$ASS, their EGFR expression levels were relatively low, and, in keeping with clinical observations for cervical cancer, they did not respond to CET as a single agent [9, 10, 44]. Our observation of increased PBNK cytotoxicity upon combination with CET is in line with a report by Meira et al. [45] who showed that one of the antitumor effector mechanisms upon combined CET and chemoradiation actually was ADCC.

Next, we compared the functionality of PBNK with that of ex vivo generated UCB-NK derived from cord blood
Fig. 4 Effects of NK inhibitory ligands on NK cytotoxicity against cervical cancer cells. 

a Percentage of positive cells within the NK cell population for NK inhibitory receptors KIR2D and CD94/NKG2A for PBNK only, PBNK stimulated with cytokines (IL-2 + IL-15) and UCB-NK only were determined by flow cytometry. The data presented is from three representative donors for PBNK and UCB-NK. PBNK only are denoted by open circles, PBNK (IL-2 + IL-15) are denoted by closed circles and UCB-NK by closed squares. 

b Representative histogram plots showing geometric mean fluorescence intensity (MFI) of NK inhibitory ligands HLA-ABC, HLA-E and HLA-G on cervical cancer cells; representative plots of 2–3 separate analyses are shown. Correlation analysis of MFI of HLA-ABC with % cytotoxicity (Δ7AAD) by c PBNK, d PBNK + cetuximab (CET) and e UCB-NK. Dotted lines represent 95% confidence interval of the regression line.

Four experiments with four different PBNK donors for C33A, HeLa, SiHa, CC11B, CC11A, CC10B, CC10A, CaSki, two experiments with two different PBNK donors for CSCC7 and CC8 and five experiments with five different UCB-NK donors were used for this experiment. 
P value was calculated with Pearson’s analysis.
stem cells and showed that UCB-NK were significantly more cytotoxic than PBNK (Fig. 2). NK cytotoxicity and NK degranulation levels were equivalent for UCB-NK and PBNK + CET. Further study of the NK killing mechanism revealed that the cytotoxic activity of both PBNK and UCB-NK was at least in part dependent on DNAM-1 and NKG2D receptors, as also previously reported for an NK cell line (NKL) and cytotoxicity it induced in the CaSki and SiHa cell lines [18]. This was in keeping with high expression levels of both NKG2D and DNAM-1 observed on both PBNK and UCB-NK. As complete abrogation of tumor cell killing was not achieved by combined blocking of DNAM-1 and NKG2D on activated PBNK and UCB-NK, other NK killing mechanisms such as NKp44/NKp44L, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and FAS (Fas ligand interactions) also might contribute to the observed target cell lysis [46, 47]. Indeed, NKp44 has been previously reported as highly expressed on expanded UCB-NK, in sharp contrast to PB-NK cells, which in the steady state do not express NKp44 [32]. The known ligands for NKp44 have mostly been associated with microbial responses, whereas the identity of cancer-associated ligands until recently has remained mostly obscure. A ligand for NKp44 has now been identified on tumor cells, designated NKp44L, which opens the way for further exploration of the relative importance of this activating receptor axis in NK-mediated tumor cytolysis [48].

Interestingly, in the present study, we have shown the predominant effect of HLA class I expression on the functionality of PBNK. In contrast to PBNK, UCB-NK have the ability to overcome resistance to cytolysis due to HLA-ABC expression as demonstrated by the correlative studies with all ten cell lines which revealed efficient UCB-NK-mediated cytolysis of both HLA-ABC high- and low-expressing cell lines (Fig. 4c). A lack of expression of inhibitory KIRs on UCB-NK may provide a mechanistic explanation for their ability for HLA class I independent cytotoxicity. Indeed, whereas PBNK and UCB-NK expressed similar levels of NKG2A, inhibitory KIRs, as measured by a panKIR2D antibody, were completely lacking from the UCB-NK cell surface. In keeping with this observation, we previously published the profiling of UCB-NK using an expanded panel of antibodies to inhibitory KIR, which revealed low expression levels of KIR2DL1/DS1, KIR2DL2/DS3/DS2 and KIR3DL1/DS1 as compared to PBNK [32]. Cervical tumors have been shown to also have aberrant non-classical HLA class I expression which might help them to escape from NK cell killing (Heeren et al. 2016, submitted). Remarkably, in our hands, NK cytotoxicity was not impaired by higher levels of HLA-E or HLA-G expression. The apparent ability of UCB-NK to overcome the possible resistance related to expression of both inhibitory classical and non-classical HLA molecules may offer an excellent treatment modality for cervical cancer.

NK cells are often dysfunctional and low in number in cervical cancer patients [18, 22, 23]. In order to achieve a more potent and effective cytotoxic effect of NK cells in patients with cervical cancer, it is therefore critical to have adequate numbers of functional effector NK cells. In regard to generating large numbers of NK cells for therapeutic purposes, NK cells expanded from PBMC and other sources have limited expansion capacity as compared to cord blood-derived NK cells [49]. Adoptive transfer of large numbers of cytotoxic UCB-NK could be a viable treatment option, because UCB-NK have a highly activated phenotype with more than 75 % stable expression rates of NKG2D, DNAM-1, Nkp30, Nkp44 and Nkp46 in all mature UCB-NK, and lack inhibitory KIRs, resulting in HLA-independent cytolytic efficacy; additional advantages of UCB-NK over PBNK are fewer impurities (such as T and B cells) detected upon full NK maturation, thereby reducing chances of GVHD upon adoptive transfer [30, 36]. In this study, UCB-NK were not tested in combination with CET due to their low surface expression of CD16a in vitro; however, UCB-NK further mature upon adoptive transfer in vivo which is accompanied by an increase in CD16a expression [50], and this feature could be exploited to enhance tumor killing even more via ADCC using CET and other IgG1 therapeutic antibodies. To facilitate clinical application, a GMP-based NK cell expansion and differentiation protocol has already been established, approved by regulatory authorities and applied in a Phase-I clinical trial for elderly acute myeloid leukemia patients and numbers of over 30 × 10^9/kg body weight cytotoxic UCB-NK (oNKord®) can easily be achieved for therapeutic purposes (CCMO no NL31699 and Dutch trial register no 2818). Therefore, it is now entirely feasible to develop clinical protocols to explore, for the first time, adoptive transfer of UCB-NK in patients with solid tumors like cervical cancer.

In conclusion, our data provide a clear rationale for the use of UCB-NK to treat cervical tumors and also the possibility of using PBNK in combination with CET for EGFR-expressing tumors, with both significantly higher cytotoxicity and degranulation levels than in PBNK only conditions. Notably, treatment with UCB-NK might serve as a generally applicable treatment for cervical cancer enabled by HLA-, histology- and HPV-independent killing mechanisms.

Acknowledgments We would like to thank Martijn Bogaarts from the Department of Pathology, VU University Medical Center (Amsterdam, The Netherlands) for technical assistance. We would like to thank all healthy donors who volunteered to give blood for this study. In addition, we would like to thank the Rational molecular Assessments and Innovative Drugs selection (RAIDs) 7th Framework
Program Consortium for providing the RAS mutational data on three cell lines included in this study.

**Funding** This work was supported by research grants from the Dutch Cancer Society (KWFVU2013-6015) and the Marie Curie Initial Training Network—The Natural Killer Cell-Based Anti-Cancer Immunotherapies—funded by the European Commission 7th Framework Program (317013).

**Compliance with ethical standards**

**Conflict of interest** J. P. Veluchamy and J. Spanholz are the employees of Glycostem Therapeutics; D. Heideman serves on scientific advisory boards of Amgen and Pfizer. The other authors declare no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1):S1–15
2. Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11–22
3. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ (2014) Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 14:395–405
4. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R (2012) Molecularely targeted therapies in cervical cancer: a systematic review. Gynecol Oncol 126:291–303
5. Diaz-Padilla I, Monk BJ, Mackay HJ, Oakein A (2013) Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 85:303–314
6. Li Q, Tang Y, Cheng X, Ji J, Zhang J, Zhou X (2014) EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol 7:733–741
7. Kersemakers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J et al (1999) Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5:577–586
8. Schrevel J, Gorter A, Kolkman-Uljee SM, Trimbos JB, Fleuren GJ, Jordanova ES (2011) Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol 24:720–728
9. Hertlein L, Lenhard M, Kirschenhofer A, Kahler S, Mayr D, Burges A et al (2011) Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 283:109–113
10. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT et al (2011) Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 121:303–308
11. Menderes G, Black J, Schwab CL, Santin AD (2016) Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther 16:83–98
12. Connor ME, Stern PL (1990) Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 46:1029–1034
13. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG et al (2008) Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14:2028–2035
14. Akira S, Umematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
15. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510
16. Vitale M, Cantoni C, Pietra G, Mangari MC, Moretta L (2014) Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44:1582–1592
17. Kobayashi A, Greenblatt RM, Anastas K, Minkoff H, Massad LS, Young M et al (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64:6766–6774
18. Teztor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ et al (2008) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123:2343–2353
19. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH et al (2011) HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci USA 108:10656–10661
20. Renoux VM, Bisig B, Langers I, Dortu E, Clemenceau B, Thiry M et al (2011) Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 41:3240–3252
21. Jimenez-Perez MI, Jave-Suarez LF, Ortiz-Lazareno PC, Bravo-Cuellar A, Gonzalez-Ramella O, Aguilar-Lemarroy A et al (2012) Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications. BMC Immunol 13:7
22. Arreygue-Garcia NA, Danert-Navarro A, Del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF et al (2008) Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 8:16
23. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG et al (2009) Low NKP30, NKP46 and NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 9:186
24. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES (2012) HLA-E expression in cervical adencarcinomas: association with improved long-term survival. J Transl Med 10:184
25. Gimenes F, Teixeira JJ, de Abreu AL, Souza RP, Pereira MW, da Silva VR et al (1846) Human leukocyte antigen (HLA)-G and cervical cancer immunoeediting: a candidate molecule for therapeutic intervention and prognostic biomarker? Biochim Biophys Acta 576–589:2014
26. Cho H, Chung JY, Kim S, Braunschweig T, Kang TH, Kim J et al (2014) MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 14:957
27. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA et al (2011) A phase II study of allogeneic natural killer cell
therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98–107
28. Miller JS, Soginier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057
29. Geller MA, Miller JS (2011) Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3:1445–1459
30. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T et al (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 6:e20740
31. Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4:76
32. Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, Bilban M et al (2012) Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem Cells Dev 21:2926–2938
33. Koopman LA, Szuhai K, van Eendenburg JD, Bezrookove V, Kenter GG, Schuuring E et al (1999) Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res 59:5615–5624
34. Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF et al (2009) A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol 31:329–333
35. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA et al (2012) KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 14:247–255
36. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I et al (2010) High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS ONE 5:e9221
37. Campbell KS, Hasegawa J (2013) Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132:536–544
38. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299–308
39. Wang M, Yin B, Wang HY, Wang RF (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:1265–1278
40. Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578
41. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:1543–1550
42. Goncalves MA, Le DM, Simoes RT, Rabreau M, Soares EG, Donadi EA, Carosella ED (2008) Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 141:70–74
43. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762
44. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G et al (2007) Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 106:513–520
45. Meira DD, de Almeida VH, Mororo JS, Nobrega I, Bardella L, Silva RL et al (2009) Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer 101:782–791
46. Warren HS, Smyth MJ (1999) NK cells and apoptosis. Immunol Cell Biol 77:64–75
47. Boerman GH, van Ostaijen-ten Dam MM, Kraal KC, Santos SJ, Ball LM, Lankester AC et al (2015) Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother 64:573–583
48. Vieillard V, Baychelier F, Debre P (2014) NKp44L: a new tool for fighting cancer. Oncoimmunology 3:e27988
49. Cheng M, Chen Y, Xiao W, Sun R, Tian Z (2013) NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 10:230–252
50. Cany J, van der Waart AB, Tordoir M, Franssen GM, Hungalapura BN, de Vries J et al (2013) Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS ONE 8:e64384